Neurorehabilitation: Transforming lives via interdisciplinary approach for atypical Parkinsonism: Dr. Vignesh Srinivasan & Dr. Poovarasan Wednesday, August 6, 2025, 08:00 Hrs [IST ...

Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434 in MSA – MELBOURNE, Australia and SAN FRANCISCO, (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ...

About 90,000 people are diagnosed with Parkinson's disease (PD) each year—one person every six minutes. While most people ...

For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of dopaminergic neurons in the substantia nigra is well recognized and ...

Dogs' noses are sensitive enough to track down fleeing convicts, locate human remains in hidden burial sites and detect illicit drug stashes.

Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder worldwide, is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a ...

*** man sucked into an MRI machine at Nassau Open MRI on Old Country Road in Westbury. Police say the 61 year old went into the room Wednesday while *** scan was in progress. They say *** large ...

*** man sucked into an MRI machine at Nassau Open MRI on Old Country Road in Westbury. Police say the 61 year old went into the room Wednesday while *** scan was in progress. They say *** large ...

Scientists have developed a long-acting injectable treatment combining levodopa and carbidopa, the two medications used to treat Parkinson’s, which could transform how the disease is treated.

The findings of two recent studies give hope that the disease could one day be reversed in humans—but experts warn that this complex disease will likely need multiple complementary treatments.

A common virus once thought harmless to humans might be linked to Parkinson's disease, a new study says. The germ, Human Pegivirus (HPgV), was found in half the autopsied brains of patients with ...

A new Stanford Medicine study reveals a promising approach to slowing Parkinson's disease by targeting overactive LRRK2 enzymes with an MLi-2 inhibitor, showing neuron restoration in mice.